Candel Therapeutics (CADL) Non Operating Income (2020 - 2025)
Candel Therapeutics (CADL) posted Non Operating Income of -$13.7 million for Q4 2025, down 809.18% sequentially from $1.9 million in Q3 2025, and down 131.69% YoY from $43.4 million in Q4 2024.
Candel Therapeutics (CADL) Non Operating Income (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Non Operating Income for 6 years, with the latest figure at -$13.7 million in Q4 2025.
- Quarterly Non Operating Income fell 131.69% year-over-year to -$13.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.1 million (up 146.24% YoY) and the FY2025 annual result came in at $10.1 million, up 146.24% from the prior year.
- Non Operating Income eased to -$13.7 million in Q4 2025 per CADL's latest filing, from $1.9 million in the prior quarter.
- Over five years, Non Operating Income peaked at $15.5 million in Q1 2025 and troughed at -$13.7 million in Q4 2025.
- A 5-year average of -$287000.0 and a median of $186000.0 in 2021 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income tumbled 38945.71% in 2024, then jumped 4961.76% in 2025.
- Over 5 years, Non Operating Income stood at $9.3 million in 2021, then slumped by 67.67% to $3.0 million in 2022, then tumbled by 125.75% to -$777000.0 in 2023, then sank by 663.45% to -$5.9 million in 2024, then plunged by 131.69% to -$13.7 million in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$13.7 million, $1.9 million, and $6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | -13.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13.74 Mn |
| Sep 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Mar 31, 2025 | 15.51 Mn |
| Dec 31, 2024 | -5.93 Mn |
| Sep 30, 2024 | -1.89 Mn |
| Jun 30, 2024 | -13.67 Mn |
| Mar 31, 2024 | -319,000.00 |
| Dec 31, 2023 | -777,000.00 |
| Sep 30, 2023 | 426,000.00 |
| Jun 30, 2023 | -35,000.00 |
| Mar 31, 2023 | 838,000.00 |
| Dec 31, 2022 | 3.02 Mn |
| Sep 30, 2022 | 193,000.00 |
| Jun 30, 2022 | 4.60 Mn |
| Mar 31, 2022 | 8.11 Mn |
| Dec 31, 2021 | 9.34 Mn |
| Sep 30, 2021 | -8.13 Mn |
| Jun 30, 2021 | -11.78 Mn |
| Mar 31, 2021 | 179,000.00 |